Skip to main content
Home / Press Room / HONG KONG-BASED EMERGING VIRAL DIAGNOSTICS (HK) LIMITED RECEIVES PRESTIGIOUS "2023 DELOITTE CHINA LIFE SCIENCES & HEALTHCARE RISING STAR" AWARD
2024-01-15
HONG KONG-BASED EMERGING VIRAL DIAGNOSTICS (HK) LIMITED RECEIVES PRESTIGIOUS "2023 DELOITTE CHINA LIFE SCIENCES & HEALTHCARE RISING STAR" AWARD

[Hong Kong, January 15, 2024] - Emerging Viral Diagnostics (HK) Limited (EVDL), a homegrown start-up comprising medical doctors, experienced scientists, and engineers, proudly announces its recognition as the sole Hong Kong awardee of the esteemed "2023 Deloitte China Life Sciences & Healthcare Rising Star" accolade. This prestigious recognition underscores EVDL's commitment to providing innovative solutions to unmet medical needs.

EVDL's team of multidisciplinary professionals, with expertise ranging from scientific research to manufacturing, has successfully developed the Avalon Automated Multiplex System (AAMST). AAMST revolutionizes Point-of-Care Testing (POCT) by offering a low-cost yet highly effective comprehensive diagnostic solution. AAMST fully automates conventional lab-based PCR processes in an all-in-one system with three major components - the Analytic Machine (AAMA), the Microfluidic Cartridge (AAMC), and the
Software (AAMS) - and allows simultaneous detection of 40 pathogens in approximately an hour, including viruses, bacteria, & fungi, with extremely high sensitivity & specificity. Pre-clinical evaluation has been done in Centre for Health Protection (CHP), Queen Mary Hospital and Queen Elizabeth Hospital with satisfactory results. The AAMC is customizable based on market needs, from clinical (respiratory diseases, cancers) to non-clinical (environmental, veterinary, food safety) applications. AAMST’s multiplexing capability, affordable pricing and its versatility will bring revolutionary change in the diagnostic industry. From prompt diagnosis to environmental surveillance, it offers a solution against potential future epidemics.

"We are honoured to be recognized as the recipient of the '2023 Deloitte China Life Sciences & Healthcare Rising Star' award," said Dr. Manson Fok, Co-Founder and Chairman of EVDL. "This achievement is a testament to our team's unwavering dedication and passion for addressing unmet medical needs through innovative diagnostic solutions. We are committed to advancing healthcare and improving patient outcomes through our cutting-edge technology."

“We are proud to have an innovative technology that is fully designed, developed and manufactured locally, “ said Prof. Terence Lau, Co-Founder and President of EVDL. “With tremendous support from the Government of HKSAR and the People’s Government of Pingshan District, Shenzhen, Guangdong Province, China, we are ready to serve the local community with our three manufacturing sites in the Greater Bay Area in compliance with ISO 13485 standard.”

This prestigious award highlights the significant contributions of EVDL to the healthcare industry and reinforces our position as a leading innovator in the diagnostics field. EVDL remains devoted to transforming the paradigm of medical testing and delivering practical solutions to benefit communities in the Greater Bay Area and beyond. Our vision, 'Diagnosis beyond Boundaries', encapsulates our mission to not only transcendgeographical limits, but also to constantly elevate diagnostic capabilities to new heights.

Award device

Accompanied by Dr. Manson Fok, Co-Founder and Chairman of Emerging Viral Diagnostics (first left), Prof. Terence Lau, Co-Founder and President of Emerging Viral Diagnostics (middle), introduced EVDL’s manufacturing site in MARS Centre at the Tai Po InnoPark, managed and operated by the Hong Kong Science and Technology Parks Corporation (HKSTP), and its innovation “Avalon Automated Multiplex System” to Mr. David Yu, Regional Audit leader in Southern Region Mainland, Audit & Assurance of Deloitte (first right).


Image removed.
Both the Deloitte and EVDL teams joined the "2023 Deloitte China Life Sciences & Healthcare Rising Star” award presentation.


Manson Terence
Co-Founders of Emerging Viral Diagnostics, Prof. Terence Lau (left) and Dr. Manson Fok (right), and the EVDL team remain devoted to transforming the paradigm of medical testing and delivering practical solutions to benefit communities in the Greater Bay Area and beyond.

Mr David Yu
Mr. David Yu, Regional Audit leader in Southern Region Mainland, Audit & Assurance of Deloitte, gives a thumbs up to EVDL’s Avalon Automated Multiplex System.

AWARD
The "2023 Deloitte China Life Sciences & Healthcare Rising Star” Award.

About Deloitte China Life Sciences & Healthcare (LSHC) Rising Star
The “Deloitte China LSHC Rising Star” Program is an extension of Deloitte’s “Technology Fast” Program, aiming to recognize outstanding companies that have achieved leadership in their niche areas in LSHC industry and have great growth potential, and allow new fast growing and innovative companies to become recognized and rewarded through Deloitte China program.“Technology Fast” program was founded in 1995 in Silicon Valley and launched in 2005 in China. This program recognizes outstanding companies that continue to innovate and grow at high rates. “Technology Fast” has generated many rising stars and future industry leaders in the past—Chinese companies becoming global leaders for many of them, as notable winners in recent years include Tencent, Jingdong, Bytedance, Mindray, WuXi AppTec, Innovent, etc.